Compass Therapeutics, Inc. (CMPX) Research
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Market snapshot
- Symbol
- CMPX
- Price
- $2.02
- Day change
- -1.46%
- Market cap
- $279.3M
- P/E ratio
- -5.52x
- 52-week range
- 1.61-6.88
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $10.40
Recent news
- Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
Compass Therapeutics Inc. (NASDAQ:CMPX) shares are tumbling on Monday as the company announced results from its COMPANION-002 study, which evaluated its drug tovecimig in patients with advanced biliary tract cancer.
Peer companies
Recent insider activity
- Lerner Neil — P-Purchase (15000 shares) on 2026-04-29
- Anderman Jonathan — P-Purchase (25000 shares) on 2026-04-29
- Anderman Jonathan — A-Award (25000 shares) on 2026-04-29
- Lerner Neil — A-Award (15000 shares) on 2026-04-29
- Schuetz Thomas J. — F-InKind (36687 shares) on 2026-02-08
Open Compass Therapeutics, Inc. (CMPX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.